devdiscourse3h
AI steps up in the battle against diabetes complications
AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...
EyePoint stock jumps 10% on Duravyu study results
EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.
'Good' cholesterol might not be so good for glaucoma
The cholesterol that's good for your heart health might be bad for your eye health and vice versa, a new study says.
CNET on MSN8h
Protect Your Eyes: 10 Simple Hacks for Better Vision
The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...
PharmiWeb10h
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
'Good' cholesterol may be linked to heightened glaucoma risk among over 55s
"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
DVLA lists every condition you need to declare or face £1,000 fine
It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...
Pharm Exec23h
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Business Wire23h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...